- Report
- August 2024
- 200 Pages
Global
From €3678EUR$3,869USD£3,090GBP
- Report
- September 2024
- 343 Pages
Global
From €4562EUR$4,799USD£3,833GBP
- Report
- November 2024
- 239 Pages
Global
From €3969EUR$4,175USD£3,334GBP
- Report
- April 2024
- 402 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 186 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 199 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 192 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 198 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 198 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- August 2024
- 200 Pages
Global
From €2177EUR$2,290USD£1,829GBP
- Report
- July 2024
- 180 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 391 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 262 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 762 Pages
Global
From €5514EUR$5,800USD£4,632GBP
- Report
- March 2025
- 182 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 93 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 274 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 334 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 292 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP

The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less Read more